Dataset from A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008818
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objective:
To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to
week 26 in patients with type 2 diabetes mellitus.
Secondary Objective:
To compare overall efficacy and safety of LixiLan to insulin glargine over 26 weeks in
patients with type 2 diabetes mellitus.
创建时间：
2024-11-26
